We are looking forward to the RESI conference, where we will present our exciting growth opportunity to investors and other interested parties
As an active member of the biologics and regenerative medicine community, we are looking forward to the discussions at this meeting
Our CEO, Graeme Brookes, is an invited panel member for the CEO Panel discussion during the meeting
We look forward to discussing our unique investment opportunity at this key event
Once again, we look forward to being part of continuing to build and strengthen Danish-US life science connections
We look forward to seeing friends and contacts at the SAWC
We will attend the whole conference and will also present at the ‘New Technologies in Wound Care’ Symposium in the Budapest Room at the congress centre on Thursday, May 10th 16.00 - 17.00
06 September 2015
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that a key patent has been granted in the Japan.
12 August 2015
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification of key patents grants in China and Canada.
19 May 2015
A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective in healing diabetic foot ulcers.
17 March 2015
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.
28 November 2014
Reapplix was today announced as the winner of ‘The Engineer’ Product Prize 2014 in the Innovation category. The Engineer’s Product Prize is a prestigious award recognising technologically advanced products that are both novel and are based on significant technical skills and knowledge.
Commenting on the award, the judges stated that “LeucoPatch solves a significant problem among diabetics. It is simple to use and it utilizes the body’s own biology. The product reflects thorough research and has very significant knowledge built into it. Therefore, it wins the Innovation Award.”
27 November 2014
Reapplix was chosen from the selected participants in the 2014 EY Entrepreneur Of The Year in Denmark as a top 3 finalist in the Life Sciences category. This provided the opportunity to showcase both the company and the LeucoPatch technology in a short film presented to industry and business leaders assembled at the prestigious EY Entrepreneur Of The Year awards event in Copenhagen on 27 November 2014.
22 September 2014
Reapplix announces that the Centers for Medicare and Medicaid Services in the USA have approved Reapplix’s clinical research study protocol for Coverage with Evidence Development.
10 September 2014
Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer.
13 August 2014
17 July 2014
“Lise Tarnow, TV2 Lorry”:http://www.tv2lorry.dk/arkiv/2014/7/14?video_id=93064